Pleco has successfully created a model system for studying the way sub-toxic accumulation of multiple metals interacts with cancers and chemotherapy. This is the first time such a model has been created. Its significance is in the possibilities it creates for studying chelation therapy in relation to metal-associated cancers such as AML and SCLC, and likely many other types of cancer.
Pleco's end products are carefully optimized products that include chelating agents with specific characteristics. Current research efforts focus on testing tailored compositions that show high potential in removing toxic metals while sparing essential metals.
We have developed a diverse pipeline with several products in preclinical development. The lead compound is currently being tested in the clinic.